HIV INTEGRASE INHIBITORS

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

International Journal of PharmATA
Volume:3 Issue:1
HIV INTEGRASE INHIBITORS

HIV INTEGRASE INHIBITORS

Authors : Ferhat GÜNEŞ

Pages : 23-30

View : 25 | Download : 9

Publication Date : 2023-01-04

Article Type : Review Paper

Abstract :HIV infection is incredibly detrimental and fatal to people. Unfortunately, despite recent advancements and medications, it has not yet been completely eradicated. Opportunistic infections are added to the list of disorders in AIDS insert ignore into journalissuearticles values(Acquired Immune Deficiency Syndrome);, an infectious disease that develops as a result of an impaired immune system. In 2021, there were 38.4 million [33.9-43.8 million] persons living with HIV worldwide, up from 26.0 million [22.9-29.7 million] in 2000. The benefits of vastly expanded access to antiretrovirals, which have contributed to decreasing the number of individuals dying from HIV-related causes, can be observed in the persistence of HIV transmission despite declines in incidence. HIV-1 integration insert ignore into journalissuearticles values(IN);, a critical stage in the integration of viral DNA into the host genome, is vital for retroviral replication. Numerous HIV integrase inhibitors have been created since the identification of this pathway, including Raltegravir, Elvitegravir, Dolutegravir, Bictegravir, and Cabotegravir. HIV integrase inhibitors and their synthesis are covered in this review.
Keywords : Hiv, Integrase inhibitors, AIDS

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.